13 Ways To Create A Sustainable Biosimilars Market In Europe

28 Sep 2016
Analysis

Ian Schofield @ScripIanS ian.schofield@informa.com

Executive Summary

More alignment between manufacturers and national payers is needed on issues such as price, competition and the role of payer guidance if the biosimilars market is to be sustainable over the longer term, says a new report.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Biosimilars Market Access Europe

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS119205

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS119205

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

13 Ways To Create A Sustainable Biosimilars Market In Europe

Analysis

Executive Summary

Related Content

EU’s CHMP Expected To OK Another Biosimilar Humira

EU’s CHMP Expected To OK Another Biosimilar Humira

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert